Docoh
Loading...

AWH Aspira Women`s Health

Aspira Women's Health Inc. operates as a biotech company. The Company develops and discovers testing and treatments for gynecologic issues. Aspira Women's Health serves customers in the State of Texas.

Company profile

Ticker
AWH
Exchange
Website
CEO
Valerie Palmieri
Employees
Incorporated
Location
Fiscal year end
Former names
CIPHERGEN BIOSYSTEMS INC, VERMILLION, INC.
SEC CIK
IRS number
330595156

AWH stock data

(
)

Investment data

Data from SEC filings
Securities sold
Number of investors

Calendar

14 May 21
2 Aug 21
31 Dec 21
Quarter (USD)
Mar 21 Dec 20 Sep 20 Jun 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Dec 20 Dec 19 Dec 18 Dec 17
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Cash burn rate (estimated) Burn method: Change in cash Burn method: Operating income/loss Burn method: FCF (opex + capex)
Last Q Avg 4Q Last Q Avg 4Q Last Q Avg 4Q
Cash on hand (at last report) 59.37M 59.37M 59.37M 59.37M 59.37M 59.37M
Cash burn (monthly) (positive/no burn) (positive/no burn) 1.96M 1.67M 1.75M 1.37M
Cash used (since last report) n/a n/a 8.02M 6.83M 7.16M 5.61M
Cash remaining n/a n/a 51.35M 52.54M 52.21M 53.76M
Runway (months of cash) n/a n/a 26.2 31.4 29.8 39.1

Beta Read what these cash burn values mean

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
19 Mar 21 Lafrance James T Common Stock Grant Aquire A No No 0 9,205 0 422,439
19 Mar 21 Lafrance James T Employee Stock Option Common Stock Grant Aquire A No No 7.4 15,412 114.05K 15,412
19 Mar 21 Schreiber David Common Stock Grant Aquire A No No 0 4,031 0 171,521
19 Mar 21 Jordan Veronica GH Common Stock Grant Aquire A No No 0 16,442 0 287,519
19 Mar 21 Cocozza Nancy G Common Stock Grant Aquire A No No 0 15,680 0 128,632
19 Mar 21 Palmieri Valerie Barber EMPLOYEE STOCK OPTION Common Stock Grant Aquire A No No 7.4 450,000 3.33M 450,000

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

13F holders
Current Prev Q Change
Total holders 0 0
Opened positions 0 0
Closed positions 0 0
Increased positions 0 0
Reduced positions 0 0
13F shares
Current Prev Q Change
Total value 0 0
Total shares 0 0
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Largest transactions
Shares Bought/sold Change

Financial report summary

?
Risks
  • We are currently developing multiple tests as LDTs, and intend to develop and perform LDTs at ASPiRA LABS in the future. Should FDA disagree that our tests are LDTs or decide to regulate LDTs in the future, commercialization of our diagnostic tests may be adversely affected, which would negatively affect our results of operations and financial condition.
  • We may not succeed in developing additional diagnostic products, and, even if we do succeed in developing additional diagnostic products, the diagnostic products may never achieve significant commercial market acceptance.
  • The diagnostics market is competitive, and we may not be able to compete successfully, which would adversely impact our ability to generate revenue.
  • If we or our suppliers fail to comply with FDA requirements for production, marketing and post-market monitoring of our products, we may not be able to market our products and services and may be subject to stringent penalties, product restrictions or recall.
  • If our suppliers fail to produce acceptable or sufficient stock, make changes to the design or labeling of their biomarker kits or discontinue production of existing biomarker kits or instrument platforms, we may be unable to meet market demand for OVA1 and OVERA.
  • Changes in healthcare policy could increase our costs and adversely impact sales of and reimbursement for our tests, which would have an adverse effect on our business, financial condition and results of operations.
  • We are subject to environmental laws and potential exposure to environmental liabilities.
  • The operation of ASPiRA LABS requires us to comply with numerous laws and regulations, which is expensive and time-consuming and could adversely affect our business, financial condition and results of operations, and any failure to comply could result in exposure to substantial penalties and other harm to our business.
  • If we fail to maintain our rights to utilize intellectual property directed to diagnostic biomarkers, we may not be able to offer diagnostic tests using those biomarkers.
  • If a third party infringes on our proprietary rights, we may lose any competitive advantage we may have as a result of diversion of our time, enforcement costs and the loss of the exclusivity of our proprietary rights.
  • If others successfully assert their proprietary rights against us, we may be precluded from making and selling our products or we may be required to obtain licenses to use their technology.
  • The liquidity and trading volume of our common stock may be low, and our ownership is concentrated.
  • Anti-takeover provisions in our charter, bylaws, other agreements and under Delaware law could make a third-party acquisition of the Company difficult.
  • Because we do not intend to pay dividends, our stockholders will benefit from an investment in our common stock only if it appreciates in value.
  • We may need to sell additional shares of our common stock or other securities in the future to meet our capital requirements, which could cause significant dilution.
  • Because our business is highly dependent on key executives and employees, our inability to recruit and retain these people could hinder our business plans.
  • We may need to raise additional capital in the future, and if we are unable to secure adequate funds on terms acceptable to us, we may be unable to execute our business plan.
  • Business interruptions could limit our ability to operate our business.
  • The operation of ASPiRA LABS and our Aspira Synergy business depends on the effectiveness and availability of our information systems, including the information systems we use to provide services to our customers and to store employee data, and failures of these systems, including in connection with cyber-attacks, may materially limit our operations or have an adverse effect on our reputation.
  • Future litigation against us could be costly and time consuming to defend.
Content analysis
?
Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability
H.S. freshman Avg
New words: Accreditation, accredited, advisory, analytical, arm, benign, blueprint, Brigham, brought, cervical, channel, classification, classified, compensatory, conference, confirm, confirmation, Congressional, corporate, credentialled, Dana, David, de, debilitating, Deloitte, Detroit, device, director, Ellig, Endocrinology, endometrial, enhancing, eradicate, extensive, Farber, Feinstein, female, franchise, gap, Greg, group, Head, highly, Hospital, house, indeterminate, interacting, internationally, irreversibly, Leader, lifelong, LLC, Lodz, longitudinal, Michigan, microRNA, moderate, network, Nicole, Northwell, novo, OVACALC, OVASight, OVASIGHTTM, pain, partner, pathogenic, presence, President, proceeding, protocol, race, relationship, reproductive, revision, Richard, robust, Sandford, Schreiber, sequentially, source, speeding, sprint, standard, super, supplier, sustain, Synergy, SYNERGYSM, timeline, Truist, twelve, unregistered, uterine, variant, Vice, visible, visualization, vitro, Wayne
Removed: achievement, adjusted, agreed, antibody, approach, assessed, attainment, begin, billable, billing, booking, broader, capitalizing, collect, collecting, combining, commenced, computing, conserve, coupled, cumulative, dedicated, delay, demonstrated, detecting, difficulty, discontinued, earliest, end, entitled, finally, Florida, function, HBOC, hiring, historically, implement, implementation, inclusion, incorporate, insourcing, issue, labor, licensing, listing, method, multiple, Notably, offer, percentage, permitted, presurgical, publicly, published, receiving, recovery, recruitment, referral, Registration, remain, replaced, restating, reviewed, run, running, scale, schedule, scope, sector, seeking, set, software, stage, successful, supplemented, syndrome, tested, timing, titled, traction, traded, transition, underwriter, unemployment, unique, wellbeing